Lumida
/CAPR
⌘K
Capricor Therapeutics Inc

Capricor Therapeutics Inc

CAPR
$19.44USD↑+1.67%+0.32 today

MARKET CAP

1.1B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$19 – $20

52W RANGE

$4
$40

AI Summary

Stalk
TrimMedium

CAPR remains entrenched in a Stage 4 decline with clear lower highs and lower lows beneath declining EMAs. Price is extended and oversold, signaling exhaustion, but without any decisive upside displacement to invalidate bearish control. The medium-term bias stays bearish, so we defer execution until relief rallies into the EMA and prior resistance zone, where we sell into strength.

  • ↑HOPE III trial: Daromyosal slowed LV ejection decline by 91%
  • ↑FDA review on track with PDUFA set for Aug 22, 2026; no major issues raised
  • ↓Q1 2026 net loss $33.9M ($0.59/share) vs $24.4M a year earlier
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company specialized in developing innovative cellular therapies for rare diseases, particularly Duchenne muscular dystrophy (DMD). Their lead product candidate, Daromyosal, targets both skeletal and cardiac manifestations of DMD. The company is navigating pivotal regulatory pathways, aiming to become a leader in the emerging market of DMD treatments amidst significant unmet medical needs.

Bull says

  • ↑HOPE III trial: Daromyosal slowed LV ejection decline by 91%
  • ↑FDA review on track with PDUFA set for Aug 22, 2026; no major issues raised
  • ↑$279M cash, equivalents fund operating runway into Q4 2027
  • ↑High institutional interest via elevated 13F ownership suggests confidence
  • ↑Dividend yield 2.13% and positive momentum factors may attract investors
  • ↑Commercial team build-out anticipates 100+ patients post-approval transition

Bear says

  • ↓Q1 2026 net loss $33.9M ($0.59/share) vs $24.4M a year earlier
  • ↓Operating expenses jumped to $36.8M in Q1 from $25M in prior period
  • ↓Negative earnings yield and weak profitability metrics deter investors
  • ↓NS Pharma legal dispute risks Medicare patient access upon launch
  • ↓Zero revenue reported in Q1 2026; last revenue quarter was Q1 2024
  • ↓High leverage and downward analyst revisions signal selling pressure

Investment themes with CAPR

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-13-2026neutral

Transcript signals

Bull points

  • $50 million
  • We believe our current capital is sufficient to fund anticipated operating expenses and capital expenditures into the fourth quarter of 2027.
  • We believe our current capital is sufficient to fund anticipated operating expenses and capital expenditures into the fourth quarter of 2027.

Bear points

  • We're expecting that if we have to pay something back, it would be the $50 million, but we don't know.
  • There was no revenue recognized for the first quarter of 2026 or 2025.
  • net loss for the first quarter of 2026 was approximately 33.9 million or 59 cents per share compared to a net loss of approximately 24.4 million or 53 cents per share for the first quarter of 2025.
Read full transcript analysis ›